(NASDAQ: ANAB) Anaptysbio's forecast annual revenue growth rate of 5.98% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.21%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.48%.
Anaptysbio's revenue in 2026 is $234,603,000.On average, 14 Wall Street analysts forecast ANAB's revenue for 2026 to be $3,657,065,519, with the lowest ANAB revenue forecast at $2,508,888,962, and the highest ANAB revenue forecast at $4,376,921,824. On average, 12 Wall Street analysts forecast ANAB's revenue for 2027 to be $5,231,032,480, with the lowest ANAB revenue forecast at $2,508,888,962, and the highest ANAB revenue forecast at $6,372,338,203.
In 2028, ANAB is forecast to generate $8,405,414,797 in revenue, with the lowest revenue forecast at $563,465,798 and the highest revenue forecast at $20,013,097,718.